192 related articles for article (PubMed ID: 15014014)
41. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.
Sederholm C
Semin Oncol; 2002 Jun; 29(3 Suppl 9):50-4. PubMed ID: 12094340
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer.
Lim KH; Lee HY; Song SY
Chin Med J (Engl); 2013; 126(24):4644-8. PubMed ID: 24342304
[TBL] [Abstract][Full Text] [Related]
43. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
[TBL] [Abstract][Full Text] [Related]
45. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Li C; Sun Y; Pan Y; Wang Q; Yang S; Chen H
Lung; 2010 Oct; 188(5):359-64. PubMed ID: 20703493
[TBL] [Abstract][Full Text] [Related]
47. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
Choy H; Jain AK; Moughan J; Curran W; Whipple G; Demas WF; Ettinger DS
J Thorac Oncol; 2009 Jan; 4(1):80-6. PubMed ID: 19096311
[TBL] [Abstract][Full Text] [Related]
48. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C; Prisciandaro M; Milano M; Cona MS; Maggi C; Brambilla M; Mennitto A; Fabbroni C; Farè E; Cresta S; Celio L; Mariani G; Bianchi G; Capri G; de Braud F
Clin Breast Cancer; 2019 Apr; 19(2):e306-e318. PubMed ID: 30635175
[TBL] [Abstract][Full Text] [Related]
49. Gemcitabine in non-small cell lung cancer.
Crinò L; Cappuzzo F
Expert Opin Pharmacother; 2002 Jun; 3(6):745-53. PubMed ID: 12036414
[TBL] [Abstract][Full Text] [Related]
50. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
[TBL] [Abstract][Full Text] [Related]
51. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
52. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
[TBL] [Abstract][Full Text] [Related]
53. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Alami N; Page V; Yu Q; Jerome L; Paterson J; Shiry L; Leyland-Jones B
Growth Horm IGF Res; 2008 Dec; 18(6):487-96. PubMed ID: 18502161
[TBL] [Abstract][Full Text] [Related]
54. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
55. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
56. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
[TBL] [Abstract][Full Text] [Related]
57. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
60. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]